Semaglutide
Treatment for Metabolic Syndrome
Typical Dosage: 0.25mg-2.4mg weekly subcutaneous injection
Effectiveness
88%
Safety Score
60%
Clinical Trials
18
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
0.25mg-2.4mg weekly subcutaneous injection
Time to Effect
4-8 weeks for initial effects, 6-12 months for maximal weight loss
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$13,500
Monitoring:$300
Side Effect Mgmt:$150
Total Annual:$13,950
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$150,000/QALY
QALYs Gained
1.1
Outcome-Based Costs
Cost per Responder
$16,412
Cost per Remission
$34,875
Comparison vs Metformin
Cost Difference
+$13,450/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Semaglutide Outcomes
for Metabolic Syndrome
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+85%
Remission Rate
+40%
Common Side Effects
Nausea
+45%
Vomiting
+20%
Diarrhea/Constipation
+25%
Pancreatitis (rare)
+0.1%
Active Clinical Trials
15 active trials recruiting for Semaglutide in Metabolic Syndrome
Semaglutide 2.4 mg in Patients With Poor Weight-loss
NCT05073835ACTIVE NOT RECRUITINGPHASE3
70 participants
INTERVENTIONAL
London, United Kingdom
Started: Nov 1, 2022
Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
NCT06410352RECRUITINGPHASE4
220 participants
INTERVENTIONAL
Astana, Kazakhstan
Started: Mar 1, 2024
COMMETS- Combination MCI Metabolic Syndrome
NCT06072963RECRUITINGPHASE2
80 participants
INTERVENTIONAL
Ramat Gan, Israel
Started: Jan 30, 2024
Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
NCT06896981RECRUITINGPHASE2, PHASE3
30 participants
INTERVENTIONAL
Dhaka, Bangladesh
Started: Feb 1, 2025
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
NCT05586802RECRUITINGPHASE3
150 participants
INTERVENTIONAL
Lausanne, Switzerland
Started: Mar 21, 2023
Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea
NCT07281196RECRUITING
15 participants
OBSERVATIONAL
Shanghai, China
Started: Jan 1, 2025
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
NCT05819853RECRUITINGPHASE3
80 participants
INTERVENTIONAL
Aurora, United States
Started: Nov 3, 2023
Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome
NCT05702905RECRUITINGPHASE4
75 participants
INTERVENTIONAL
Beijing, China
Started: May 9, 2023
Effects of Semaglutide in HIV-Associated Lipohypertrophy
NCT04019197ACTIVE NOT RECRUITINGPHASE2
108 participants
INTERVENTIONAL
Cleveland, United States +1 more
Started: May 16, 2019
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
NCT07188545ACTIVE NOT RECRUITING
23.3M participants
OBSERVATIONAL
Columbus, United States
Started: Sep 15, 2025
The Effect of an Anti-obesity Drug, Semaglutide, As Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (dietician) with Regards to Change in Weight and Intracranial Pressure
NCT06027567ACTIVE NOT RECRUITINGPHASE4
50 participants
INTERVENTIONAL
Odense, Denmark +1 more
Started: Sep 2, 2022
Anti-obesity Pharmacotherapy and Inflammation
NCT05756764ACTIVE NOT RECRUITING
30 participants
OBSERVATIONAL
New Orleans, United States +1 more
Started: Jun 1, 2023
Metabolic Surgery for Atrial Fibrillation Elimination
NCT07027969NOT YET RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Cleveland, United States
Started: Feb 1, 2026
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
NCT07169136RECRUITING
20 participants
OBSERVATIONAL
Jacksonville, United States
Started: Sep 11, 2025
Impact GLP-1 Agonists Following Bariatric
NCT06132477RECRUITINGPHASE4
150 participants
INTERVENTIONAL
Columbia, United States
Started: Feb 1, 2024
Completed Clinical Trials
2 completed trials for Semaglutide in Metabolic Syndrome
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
NCT04216589COMPLETEDPHASE2
51 participants
INTERVENTIONAL
Birmingham, United States +8 more
Started: Feb 19, 2021
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
NCT05193578COMPLETEDPHASE2
154 participants
INTERVENTIONAL
Odense, Denmark
Started: Jan 1, 2022